/RAFA

RAFA Stock - Rafarma Pharmaceuticals, Inc.

Q: What is the analyst price target for RAFA?

Analyst price target information is not currently available for RAFA.

Q: What is RAFA's market cap?

Market capitalization information is not currently available for RAFA.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$0.03-11.76%

$0.00 (-11.76%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.03

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for RAFA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.50

52W High$0.18

52W Low$0.03

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$9.08M	$10.13M	$64.31M	$77.41M	$74.73M
Gross Profit	$674,000	$600,000	$22.81M	$27.27M	$33.08M
Gross Margin	7.4%	5.9%	35.5%	35.2%	44.3%
Operating Income	$405,000	$313,000	$7.15M	$14.72M	$19.08M
Net Income	$266,000	$273,000	$4.96M	$11.57M	$14.85M
Net Margin	2.9%	2.7%	7.7%	15.0%	19.9%
EPS	$0.00	$0.00	$0.06	$0.13	$0.17

Company Overview

Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. It offers cephalosporin-based products, antibiotics of non-ß structure, and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. The company also provides drugs for accidental wounds, inflammatory eye diseases, and immunological disorders. The company has a collaboration agreement with PlantEXT Ltd. to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company is based in Sandy, Utah with a manufacturing and distribution facility in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.

Visit Website

Frequently Asked Questions about RAFA

What is RAFA's current stock price?

Rafarma Pharmaceuticals, Inc. (RAFA) is currently trading at $0.03 per share. The stock has moved -11.76% today.

What is the analyst price target for RAFA?

No analyst price targets are currently available for this stock.

What sector is Rafarma Pharmaceuticals, Inc. in?

Rafarma Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is RAFA's market cap?

Rafarma Pharmaceuticals, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does RAFA pay dividends?

No, Rafarma Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.